Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma.
Shimura Y, Kuroda J, Uchiyama H, Kawata-Iida E, Tsutsumi Y, Nagoshi H, Mizutani S, Yamamoto-Sugitani M, Matsumoto Y, Kobayashi T, Horiike S, Shimazaki C, Kaneko H, Kobayashi Y, Taniwaki M. Shimura Y, et al. J Clin Apher. 2013 Oct;28(5):368-73. doi: 10.1002/jca.21283. Epub 2013 Jun 27. J Clin Apher. 2013. PMID: 23804501
Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.
Kiyota M, Kobayashi T, Fuchida S, Yamamoto-Sugitani M, Ohshiro M, Shimura Y, Mizutani S, Nagoshi H, Sasaki N, Nakayama R, Chinen Y, Sakamoto N, Uchiyama H, Matsumoto Y, Horiike S, Shimazaki C, Kuroda J, Taniwaki M. Kiyota M, et al. Int J Hematol. 2012 May;95(5):516-26. doi: 10.1007/s12185-012-1035-8. Epub 2012 Mar 17. Int J Hematol. 2012. PMID: 22426624
Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy.
Kuroda J, Mizutani S, Shimura Y, Maegawa S, Nagoshi H, Chinen Y, Tatekawa S, Tsukamoto T, Mizuno Y, Yamamoto-Sugitani M, Kobayashi T, Matsumoto Y, Horiike S, Taniwaki M. Kuroda J, et al. Among authors: yamamoto sugitani m. Ann Hematol. 2015 Apr;94(4):687-9. doi: 10.1007/s00277-014-2214-x. Epub 2014 Sep 12. Ann Hematol. 2015. PMID: 25209844 No abstract available.
Clinical manifestation of angioimmunoblastic T-cell lymphoma with exuberant plasmacytosis.
Nagoshi H, Kuroda J, Kobayashi T, Maegawa S, Chinen Y, Kiyota M, Nakayama R, Mizutani S, Shimura Y, Yamamoto-Sugitani M, Matsumoto Y, Horiike S, Taniwaki M. Nagoshi H, et al. Among authors: yamamoto sugitani m. Int J Hematol. 2013 Sep;98(3):366-74. doi: 10.1007/s12185-013-1411-z. Epub 2013 Aug 15. Int J Hematol. 2013. PMID: 23949915
Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma.
Chinen Y, Kuroda J, Shimura Y, Nagoshi H, Kiyota M, Yamamoto-Sugitani M, Mizutani S, Sakamoto N, Ri M, Kawata E, Kobayashi T, Matsumoto Y, Horiike S, Iida S, Taniwaki M. Chinen Y, et al. Among authors: yamamoto sugitani m. Cancer Res. 2014 Dec 15;74(24):7418-29. doi: 10.1158/0008-5472.CAN-14-1420. Epub 2014 Sep 30. Cancer Res. 2014. PMID: 25269480
22 results